BONESUPPORT HOLDING AB revenue breakdown overview

BONESUPPORT HOLDING AB revenue for the last year amounted to 52.85 M EUR, the most of which — 32.03 M EUR — came from its highest performing source at the moment, Cerament Gentamicin and Ceramanent Vancomycin, the year earlier bringing 10.01 M EUR. The greatest contribution to the revenue figure was made by North America — last year it brought BONESUPPORT HOLDING AB 39.57 M EUR, and the year before that — 19.35 M EUR.